1. A 61-year-old man with rheumatoid arthritis has been on prednisone 20 mg/day for 14 months. He presents for routine follow-up with a fasting blood glucose of 218 mg/dL, blood pressure of 148/92 mmHg, central obesity, and moon facies. His potassium is 3.9 mEq/L and sodium is 141 mEq/L. His rheumatologist explains that the hyperglycemia is a direct consequence of a specific corticosteroid mechanism and should be managed accordingly. Which of the following best identifies the mechanism responsible for the hyperglycemia and the appropriate initial management strategy?
A) The hyperglycemia results from corticosteroid-induced mineralocorticoid receptor (MR) activation in pancreatic beta cells, which reduces insulin secretion by promoting potassium efflux and membrane hyperpolarization; the appropriate initial management is spironolactone, which blocks MR in pancreatic beta cells and restores insulin secretion without requiring systemic glycemic agents.
B) The hyperglycemia results from GRE (glucocorticoid response element)-driven transactivation of hepatic gluconeogenic enzyme genes — including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase — increasing hepatic glucose output, compounded by GR-mediated reduction of peripheral glucose uptake through downregulation of GLUT4 transporters in adipose and muscle; management requires addition of glycemic therapy (metformin or insulin, depending on severity and renal function) titrated to glucose targets, while the corticosteroid dose is maintained at the minimum effective dose for disease control.
C) The hyperglycemia is caused by corticosteroid-induced destruction of pancreatic islet beta cells through a GR-mediated apoptosis pathway that is selective for insulin-secreting cells; because the beta cell loss is irreversible, corticosteroid-induced diabetes in this patient is permanent and requires insulin therapy as the only effective intervention regardless of corticosteroid dose reduction.
D) The hyperglycemia reflects pre-existing type 2 diabetes mellitus that was subclinical before prednisone therapy; corticosteroids do not cause de novo hyperglycemia in patients with previously normal glucose tolerance, and the finding should be evaluated with HbA1c testing to establish the pre-treatment baseline before attributing it to prednisone.
E) The hyperglycemia is a secondary consequence of corticosteroid-induced hypokalemia; potassium deficiency impairs insulin secretion from pancreatic beta cells, and the appropriate management is potassium supplementation and dietary sodium restriction rather than antidiabetic agents, since the glucose abnormality will resolve with electrolyte correction.
ANSWER: B
Rationale:
Corticosteroid-induced hyperglycemia is one of the most common and mechanistically well-understood metabolic adverse effects of systemic corticosteroid therapy. The mechanism operates through GRE (glucocorticoid response element)-driven transactivation — the "metabolic" arm of GR signaling. In hepatocytes, activated GR binds GREs in the promoters of gluconeogenic enzyme genes including phosphoenolpyruvate carboxykinase (PEPCK, the rate-limiting enzyme of gluconeogenesis) and glucose-6-phosphatase, upregulating hepatic glucose production. Simultaneously, GR-mediated transactivation in adipose and skeletal muscle reduces GLUT4 (glucose transporter type 4) expression and membrane translocation, impairing insulin-stimulated peripheral glucose uptake. A third component is GR-driven lipolysis — free fatty acid release from adipose tissue inhibits peripheral glucose utilization through the Randle cycle. The net result is elevated fasting glucose (from increased hepatic output) and post-prandial hyperglycemia (from reduced peripheral uptake). In this patient, the normal potassium level (3.9 mEq/L) confirms that mineralocorticoid-mediated potassium wasting is not driving the presentation; the hyperglycemia is a glucocorticoid metabolic effect. Management requires adding glycemic therapy: metformin addresses hepatic glucose output (appropriate if renal function allows) and insulin is preferred when glucose exceeds approximately 300 mg/dL or when the patient is symptomatic. Reducing the prednisone dose to the minimum effective for disease control is also an important parallel strategy.
Option A: Option A is incorrect — mineralocorticoid receptor (MR) activation in pancreatic beta cells reducing insulin secretion through potassium efflux and membrane hyperpolarization is not the established mechanism of corticosteroid-induced hyperglycemia. The normal serum potassium (3.9 mEq/L) in this patient confirms that significant MR-mediated potassium wasting is not occurring. Spironolactone is not a recognized treatment for corticosteroid-induced hyperglycemia and would not address the GRE-driven gluconeogenic enzyme upregulation.
Option C: Option C is incorrect — corticosteroids do not cause irreversible destruction of pancreatic beta cells through selective GR-mediated apoptosis. While there is some evidence that prolonged corticosteroid exposure can impair beta cell function, corticosteroid-induced diabetes does not uniformly require permanent insulin therapy; glucose tolerance frequently improves substantially when corticosteroids are tapered or discontinued. Representing the beta cell loss as irreversible and insulin as the only intervention mismanages an otherwise correctable metabolic complication.
Option D: Option D is incorrect — corticosteroids do cause de novo hyperglycemia in individuals with previously normal glucose tolerance, particularly at doses above 7.5 mg/day prednisone. The combination of increased hepatic glucose output and reduced peripheral insulin sensitivity is sufficient to cause clinically significant hyperglycemia even in patients without prior diabetes. While corticosteroids do unmask latent diabetes in susceptible individuals, the two mechanisms are not mutually exclusive, and attributing the finding entirely to pre-existing disease without addressing the corticosteroid contribution is clinically incorrect.
Option E: Option E is incorrect — this patient's potassium is 3.9 mEq/L, within the normal range, confirming that hypokalemia is not contributing to the hyperglycemia. While severe hypokalemia can impair insulin secretion, this is not the mechanism in this patient, and the normal potassium effectively excludes this explanation. Potassium supplementation and dietary sodium restriction would not address the GRE-mediated gluconeogenic enzyme upregulation driving the hyperglycemia.
2. A 44-year-old woman with ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis has been receiving prednisone 60 mg/day for 4 months as part of induction therapy. She now reports progressive bilateral hip pain with walking, worse on the right. Her DEXA (dual-energy X-ray absorptiometry) scan from 2 months ago showed mild osteopenia (T-score −1.3), and she has been taking calcium, vitamin D, and alendronate since starting prednisone. MRI of both hips reveals bilateral subchondral signal abnormality in the femoral heads with early crescent sign on the right, consistent with avascular necrosis. She asks her rheumatologist whether this complication was caused by inadequate bisphosphonate protection. Which of the following correctly explains the mechanism of this complication and why bisphosphonate therapy did not prevent it?
A) The avascular necrosis was caused by inadequate bisphosphonate dosing; alendronate at 70 mg weekly is insufficient to prevent glucocorticoid-induced osteonecrosis at prednisone doses above 40 mg/day, and the patient should have received zoledronic acid 5 mg IV annually, which provides complete protection against both osteoporosis and osteonecrosis at all corticosteroid dose levels.
B) The avascular necrosis resulted from corticosteroid-induced secondary hyperparathyroidism; high-dose prednisone suppresses intestinal calcium absorption, causing compensatory PTH (parathyroid hormone) elevation that preferentially resorbs trabecular bone in the femoral head subchondral region, and bisphosphonates are ineffective because PTH-driven resorption bypasses the farnesyl pyrophosphate synthase pathway that bisphosphonates target.
C) The avascular necrosis is unrelated to corticosteroid therapy; it reflects the underlying vasculitis causing vascular occlusion of the medial circumflex femoral artery supplying the femoral head; bisphosphonates cannot prevent vasculitis-associated vascular occlusion, and the correct management is immunosuppression escalation rather than orthopedic intervention.
D) The avascular necrosis resulted from corticosteroid-induced osteoporosis in the subchondral femoral head bone; the RANKL/OPG imbalance caused subchondral trabecular collapse before the bisphosphonate could establish sufficient osteoclast inhibition; higher-dose bisphosphonate therapy would have prevented the complication if initiated at the time corticosteroids began.
E) Avascular necrosis (osteonecrosis) is a distinct corticosteroid complication from osteoporosis and operates through a different mechanism: high-dose corticosteroids promote adipocyte differentiation in bone marrow (through GRE-driven transactivation of adipogenic transcription factors including PPARγ) and cause fat emboli in small subchondral vessels, raising intraosseous pressure and impairing the vascular supply to the femoral head; bisphosphonates target osteoclast-mediated bone resorption and cannot prevent the vascular and lipid-embolic mechanism of osteonecrosis, which is why this complication can occur despite appropriate bisphosphonate therapy.
ANSWER: E
Rationale:
Avascular necrosis (osteonecrosis) and glucocorticoid-induced osteoporosis (GIOP) are mechanistically distinct complications of corticosteroid therapy and require different preventive and therapeutic approaches. GIOP results from the RANKL/OPG imbalance producing excess osteoclast activity and simultaneous osteoblast suppression — a process that bisphosphonates directly counteract by inhibiting osteoclast function and promoting osteoclast apoptosis. Osteonecrosis occurs through a different set of mechanisms. First, high-dose corticosteroids drive mesenchymal stem cell differentiation toward adipocytes at the expense of osteoblasts through GRE-driven upregulation of adipogenic transcription factors including PPARγ (peroxisome proliferator-activated receptor gamma) and C/EBPα (CCAAT/enhancer-binding protein alpha); the result is bone marrow fat accumulation and hypertrophy that increases intraosseous pressure. Second, corticosteroids promote fat emboli in the small sinusoidal vessels of the femoral head subchondral bone, impairing blood flow. Third, corticosteroids induce apoptosis of osteocytes (the mechanosensory cells embedded in bone matrix), reducing their ability to regulate local blood flow and respond to microdamage. The combined effect is ischemic death of bone in the femoral head. Because bisphosphonates target osteoclast-mediated resorption, they cannot prevent the vascular and lipid-embolic mechanisms of osteonecrosis. Risk factors for corticosteroid-induced osteonecrosis include doses above 20 mg/day prednisone, total cumulative dose, and patient-specific vascular risk factors. No pharmacological intervention has been proven to reliably prevent it at high corticosteroid doses in high-risk patients.
Option A: Option A is incorrect — no bisphosphonate formulation, including zoledronic acid 5 mg IV annually, provides complete protection against osteonecrosis at any corticosteroid dose. This claim is pharmacologically false and does not reflect any established clinical evidence. The distinction between osteonecrosis and osteoporosis and the absence of effective pharmacological prevention for osteonecrosis are well-established in the rheumatological literature.
Option B: Option B is incorrect — corticosteroid-induced secondary hyperparathyroidism causing PTH-driven subchondral femoral head bone resorption is not the established mechanism of corticosteroid-induced osteonecrosis. While corticosteroids do impair calcium absorption and can cause secondary PTH elevation, PTH-driven trabecular resorption affects cancellous bone diffusely; it does not produce the focal subchondral signal abnormality and crescent sign that are the radiological hallmarks of osteonecrosis. The mechanism of osteonecrosis is vascular, not PTH-mediated.
Option C: Option C is incorrect — while ANCA vasculitis does cause systemic vascular inflammation, corticosteroid-induced osteonecrosis is a well-established direct complication of high-dose corticosteroid therapy that occurs across many clinical contexts, including in patients without underlying vasculitis. The bilateral femoral head involvement with the pattern described (subchondral signal abnormality, crescent sign) is classic for corticosteroid-induced osteonecrosis and should not be attributed to the underlying vasculitis without specific evidence of femoral head vessel involvement. Immunosuppression escalation would worsen the corticosteroid exposure.
Option D: Option D is incorrect — this option conflates the RANKL/OPG-mediated trabecular bone loss of osteoporosis with the focal vascular mechanism of osteonecrosis. The MRI finding (subchondral signal abnormality with crescent sign in the femoral head) is diagnostic of osteonecrosis, not generalized osteoporotic subchondral collapse. Higher-dose bisphosphonate would not have prevented this complication because bisphosphonates do not address the vascular and adipogenic mechanisms driving osteonecrosis.
3. A 28-year-old woman with moderate persistent asthma has been well-controlled on fluticasone propionate 500 μg/day plus salmeterol via a combination inhaler for 2 years. Her internist prescribes clarithromycin 500 mg twice daily for 14 days for community-acquired sinusitis. Three weeks later, she presents with weight gain of 4 kg, moon facies, easy bruising, and mild proximal weakness. Her morning serum cortisol is 0.9 μg/dL and ACTH is undetectable. Her asthma has been well-controlled throughout. Which of the following best explains her new presentation?
A) Clarithromycin, a macrolide antibiotic, is a potent inhibitor of CYP3A4 (cytochrome P450 3A4); co-administration with inhaled fluticasone propionate — a corticosteroid that normally has essentially zero oral bioavailability due to near-complete CYP3A4-mediated first-pass hepatic extraction — significantly impairs fluticasone clearance, allowing systemic accumulation of fluticasone to levels that produce glucocorticoid receptor activation in peripheral tissues, resulting in iatrogenic Cushing syndrome and secondary HPA axis suppression.
B) Clarithromycin directly activates the glucocorticoid receptor (GR) in adipocytes and hepatocytes as a partial agonist at the GR ligand-binding domain; the combined GR activation from both clarithromycin and inhaled fluticasone exceeds the threshold for HPA axis suppression, producing a pharmacodynamic synergy that is not predicted from either drug's individual dose.
C) The patient has developed a delayed macrolide hypersensitivity reaction; clarithromycin-specific IgE antibodies cross-react with fluticasone's furoate ester group, producing a mast cell-mediated reaction that drives excess cortisol secretion from the adrenal cortex through a histamine-ACTH pathway, paradoxically causing Cushing syndrome rather than anaphylaxis in this patient.
D) Clarithromycin inhibits P-glycoprotein efflux transporters in alveolar macrophages, causing intracellular accumulation of fluticasone within lung tissue at concentrations that directly suppress local adrenal precursor synthesis in lung-resident adrenocortical progenitor cells, reducing adrenal cortisol production through a local autocrine mechanism that is specific to patients with high pulmonary ICS deposition.
E) The presentation reflects natural disease progression; the patient has developed endogenous Cushing syndrome (likely a cortisol-secreting adrenal adenoma) that coincidentally became clinically apparent during the clarithromycin course; the suppressed ACTH confirms ACTH-independent hypercortisolism from an adrenal source, and the clarithromycin course is an incidental finding with no pharmacokinetic relevance.
ANSWER: A
Rationale:
This presentation is a classic example of the clarithromycin-fluticasone drug interaction, a pharmacokinetically mediated complication that is well-documented and clinically important. Fluticasone propionate normally has essentially zero oral bioavailability: the swallowed oropharyngeal fraction undergoes near-complete first-pass CYP3A4-mediated hepatic extraction before reaching systemic circulation, and the pulmonary-absorbed fraction is also rapidly cleared by CYP3A4. This pharmacokinetic barrier is what allows fluticasone to achieve high local airway concentrations with minimal systemic exposure. Clarithromycin is a potent mechanism-based (quasi-irreversible) inhibitor of CYP3A4, substantially reducing hepatic and intestinal CYP3A4 activity. When fluticasone is co-administered with clarithromycin, the CYP3A4-mediated first-pass extraction of swallowed fluticasone is markedly impaired, and the systemic clearance of pulmonary-absorbed fluticasone is also reduced. Fluticasone accumulates to systemic concentrations sufficient to activate glucocorticoid receptors in peripheral tissues including adipose, skin, bone marrow, and the hypothalamic-pituitary axis. The clinical result is iatrogenic Cushing syndrome (weight gain, moon facies, easy bruising, proximal myopathy from type IIb muscle fiber atrophy) and secondary HPA axis suppression — demonstrated by near-undetectable morning cortisol (0.9 μg/dL) and undetectable ACTH, indicating suppressed pituitary ACTH secretion from sustained exogenous corticosteroid excess. This interaction has been documented with other macrolides (erythromycin) and azole antifungals (ketoconazole, itraconazole, voriconazole) and is particularly important in patients on ritonavir-containing antiretroviral regimens who receive any ICS.
Option B: Option B is incorrect — clarithromycin is not a partial agonist at the glucocorticoid receptor and does not produce pharmacodynamic synergy with fluticasone at the GR ligand-binding domain. Clarithromycin's relevant pharmacological interaction with corticosteroids is exclusively pharmacokinetic — CYP3A4 inhibition increasing fluticasone systemic exposure — not a direct GR agonist interaction.
Option C: Option C is incorrect — macrolide hypersensitivity reactions do not cause Cushing syndrome through a histamine-ACTH pathway. There is no established mechanism by which clarithromycin-specific IgE antibodies cross-react with fluticasone's chemical structure to cause adrenal cortisol hypersecretion. The undetectable ACTH in this patient is inconsistent with ACTH-driven cortisol excess from any stimulated secretion pathway; the low ACTH confirms that cortisol excess is from an exogenous source suppressing ACTH secretion.
Option D: Option D is incorrect — clarithromycin inhibition of P-glycoprotein (P-gp) in alveolar macrophages causing intracellular fluticasone accumulation with local adrenal progenitor cell suppression is a pharmacologically fabricated mechanism with no basis in established pharmacology. The mechanism of this interaction is CYP3A4 inhibition impairing systemic fluticasone clearance, not P-gp-mediated intracellular fluticasone accumulation in the lung.
Option E: Option E is incorrect — while endogenous Cushing syndrome from an adrenal adenoma does produce the pattern of low ACTH and elevated cortisol, the timing of the presentation — developing within 3 weeks of starting a known CYP3A4 inhibitor in a patient on high-dose inhaled fluticasone — is not coincidental. Attributing the presentation to incidental adrenal adenoma without considering the clarithromycin-fluticasone interaction would be a serious diagnostic error. An adrenal adenoma would also produce an elevated, not near-undetectable, morning cortisol.
4. A 71-year-old woman has been managed for polymyalgia rheumatica (PMR) for 9 months on prednisone 15 mg/day with good symptom control. She presents to her rheumatologist with a 1-week history of new-onset bilateral temporal headaches, jaw pain when chewing, and scalp tenderness. ESR (erythrocyte sedimentation rate) is 92 mm/hr and CRP (C-reactive protein) is 28 mg/L. Physical examination reveals a thickened, tender right temporal artery. She has a temporal artery biopsy appointment scheduled for 4 days from now. Which of the following best describes the correct management at today's visit?
A) Continue prednisone 15 mg/day unchanged until biopsy results are available; the existing anti-inflammatory therapy at the current PMR maintenance dose is likely sufficient to prevent ischemic complications during the 4-day wait for biopsy, and escalating before histological confirmation risks unnecessary overtreatment with the adverse effects of high-dose corticosteroids in a 71-year-old patient.
B) Discontinue prednisone immediately and refer the patient to an ophthalmologist before any treatment decision; visual acuity testing must establish a baseline before corticosteroid escalation, since initiating high-dose therapy without a documented visual acuity baseline makes it impossible to later attribute any vision deterioration to GCA versus corticosteroid adverse effects.
C) Escalate prednisone immediately to 40 to 60 mg/day today without waiting for biopsy results; the clinical presentation — new temporal headache, jaw claudication (pain from ischemia during chewing of masseter muscles), scalp tenderness, tender thickened temporal artery, and markedly elevated inflammatory markers in a patient with known PMR — is highly consistent with GCA, and the risk of irreversible ischemic vision loss from anterior ischemic optic neuropathy justifies immediate high-dose therapy; the biopsy should still be performed as scheduled, since histological findings persist for at least 2 weeks after steroid initiation, and the result will confirm or exclude the diagnosis without requiring treatment delay.
D) Switch from prednisone to oral dexamethasone 6 mg/day, which provides equivalent anti-inflammatory potency to prednisone 40 mg/day (using the 0.75 mg dexamethasone = 5 mg prednisone equipotency ratio) while requiring only once-daily dosing; dexamethasone is preferred over prednisone for GCA because its negligible mineralocorticoid activity avoids fluid retention in elderly patients and its long biological half-life reduces the risk of off-period disease reactivation that can occur between prednisone doses.
E) Obtain urgent MRI angiography of the temporal and cranial arteries today; if vascular wall enhancement consistent with GCA is demonstrated on MRI, escalate to prednisone 40 to 60 mg/day; if MRI is negative, continue current PMR maintenance dose and defer biopsy, as a normal MRI effectively excludes GCA and makes biopsy unnecessary.
ANSWER: C
Rationale:
This patient presents with clinical features highly suggestive of giant cell arteritis (GCA) arising in the context of known polymyalgia rheumatica — a well-recognized disease association occurring in 15 to 30% of PMR patients. The new symptoms (bilateral temporal headache, jaw claudication — defined as pain and fatigue of the masseter and temporal muscles during chewing from arteritic ischemia — and scalp tenderness) combined with a palpably thickened and tender temporal artery and markedly elevated inflammatory markers constitute a compelling clinical picture of GCA. The most feared complication of untreated or undertreated GCA is permanent, bilateral ischemic vision loss from anterior ischemic optic neuropathy, which results from inflammation occluding the posterior ciliary arteries supplying the optic nerve head. This complication can develop within hours to days of symptom onset and is irreversible once established. The prednisone 15 mg/day used for PMR maintenance is inadequate to suppress the large-vessel granulomatous inflammation of GCA; GCA requires 40 to 60 mg/day. The critical clinical principle — firmly established in rheumatological guidelines — is that treatment must not wait for biopsy confirmation when the clinical picture is compelling. Temporal artery biopsy remains the diagnostic gold standard but should be performed urgently after treatment has started; histological evidence of granulomatous arteritis with giant cells, lymphocytes, and macrophages persists for at least 2 weeks after corticosteroid initiation, preserving diagnostic utility. The correct action at today's visit is to increase prednisone to 40 to 60 mg/day immediately.
Option A: Option A is incorrect — continuing prednisone 15 mg/day during a 4-day wait for biopsy in a patient with clinical features strongly consistent with GCA is dangerous and potentially negligent. This dose is completely inadequate for GCA and would not prevent progressive arterial inflammation or ischemic vision loss. The imperative to treat immediately in suspected GCA overrides the preference to confirm before treating.
Option B: Option B is incorrect — baseline visual acuity testing before treatment, while clinically sensible as documentation, is not a prerequisite that should delay corticosteroid escalation in a patient with compelling GCA features. Any delay in initiating high-dose therapy to arrange ophthalmology assessment first could result in irreversible vision loss during the waiting period. The correct approach is to escalate corticosteroids today and arrange ophthalmological assessment as an urgent parallel step.
Option D: Option D is incorrect — while the dose equivalence calculation is approximately correct (dexamethasone 6 mg ≈ prednisone 40 mg), dexamethasone is not preferred over prednisone for GCA. Dexamethasone's biological half-life of 36 to 54 hours makes alternate-day therapy impossible (eliminating the HPA-sparing option for long-term use) and makes it particularly prone to HPA axis suppression during the months of therapy required for GCA. Prednisone/prednisolone is the standard agent for GCA induction and maintenance therapy in all major guidelines.
Option E: Option E is incorrect — while MRI angiography can demonstrate vessel wall enhancement in GCA and is a useful adjunct diagnostic tool, a normal MRI does not effectively exclude GCA, particularly in a patient with highly suggestive clinical features. MRI sensitivity for GCA is imperfect, and a negative MRI in a high-probability clinical scenario should not be used to avoid biopsy or delay treatment. The correct approach does not require imaging confirmation before treatment escalation when clinical probability is high.
5. A 45-year-old man with ileocolonic Crohn's disease has been maintained on oral budesonide 9 mg/day (controlled-release formulation) for 6 months. At his follow-up visit, he asks his gastroenterologist why this formulation does not cause the same systemic side effects — weight gain, hyperglycemia, skin changes — that he experienced during a course of prednisone 40 mg/day three years ago. The gastroenterologist explains that the favorable side effect profile is due to a specific pharmacokinetic design feature of the oral budesonide formulation. Which of the following best explains this feature?
A) Oral budesonide is a prodrug that requires ileal mucosal esterases to convert it to the active form; the active metabolite is generated exclusively at the mucosal surface and is too hydrophilic to be absorbed into the portal circulation, confining all glucocorticoid receptor activation to the intestinal mucosa without any possibility of systemic exposure.
B) Oral budesonide is encapsulated in pH-sensitive microcapsules that dissolve only in the alkaline environment of the terminal ileum and colon, where it activates exclusively at the luminal surface through a non-absorbed surface receptor mechanism; because the drug never crosses the mucosal epithelium, it cannot reach systemic circulation regardless of how much is ingested.
C) Oral budesonide binds irreversibly to glucocorticoid receptors in ileal and colonic epithelial cells, producing permanent local receptor occupancy that sustains anti-inflammatory effect for months after a single course; systemic effects are absent because the irreversible binding traps budesonide at its site of action and prevents free drug from entering the portal circulation.
D) The controlled-release oral budesonide formulation is designed to deliver drug to the terminal ileum and right colon, where it is absorbed locally and produces high luminal and mucosal tissue concentrations; the absorbed drug then enters the portal circulation and undergoes approximately 90% first-pass hepatic CYP3A4-mediated metabolism before reaching systemic circulation, leaving only approximately 10% oral bioavailability — this extensive first-pass extraction produces high local mucosal drug concentrations with minimal systemic exposure, explaining the absence of systemic corticosteroid side effects at the 9 mg/day dose.
E) Oral budesonide at 9 mg/day is a sub-therapeutic dose that does not achieve glucocorticoid receptor occupancy sufficient to produce systemic effects; the apparent anti-inflammatory benefit in this patient's Crohn's disease reflects a placebo response and the natural relapsing-remitting course of the disease rather than pharmacologically meaningful GR activation.
ANSWER: D
Rationale:
Oral budesonide for Crohn's disease is a pharmacological success story built on the same principle as inhaled corticosteroids: achieving high local concentrations at the target tissue (in this case, the terminal ileal and right colonic mucosa) while minimizing systemic exposure through extensive first-pass hepatic metabolism. The controlled-release formulation (Entocort EC or equivalent) uses a pH- and time-dependent release system that delivers budesonide to the terminal ileum and proximal colon — the sites most commonly affected in ileocolonic Crohn's disease. After local release, budesonide is absorbed across the intestinal epithelium and enters the portal circulation. In the liver, it undergoes approximately 90% first-pass CYP3A4-mediated metabolism to inactive metabolites (16α-hydroxyprednisolone and 6β-hydroxybudesonide), resulting in an oral systemic bioavailability of approximately 10% — compared to prednisone's approximately 80% systemic bioavailability after absorption. The consequence is that the mucosal and portal blood concentrations achieved at 9 mg/day are sufficient to activate GR in intestinal mucosal inflammatory cells, suppress NF-κB-driven cytokine production, and reduce mucosal inflammation, while the systemic plasma concentrations are too low to produce the cushingoid features, hyperglycemia, and HPA axis suppression associated with equivalent anti-inflammatory doses of prednisone. This pharmacokinetic design — high local concentration + rapid first-pass clearance — is precisely the ICS principle applied to the GI tract. Note that at doses above 9 mg/day or in patients with severe hepatic dysfunction, the first-pass extraction may be insufficient to prevent systemic effects.
Option A: Option A is incorrect — oral budesonide is not a prodrug requiring ileal esterase activation. Budesonide is the pharmacologically active compound as administered. The intrapulmonary fatty acid ester formation of budesonide (relevant to the inhaled form) is an intracellular retention mechanism in lung cells, not a mucosal activation step for the oral form. Additionally, the claim that the active metabolite is too hydrophilic to be absorbed into the portal circulation is incorrect; budesonide is a lipophilic steroid that readily crosses epithelial membranes.
Option B: Option B is incorrect — oral budesonide is absorbed across the intestinal epithelium and does enter the portal circulation; it is not confined to the luminal surface through a non-absorbed receptor mechanism. The pH-sensitive microcapsule delivery system controls the anatomical site of drug release (targeting terminal ileum and right colon), but once released, budesonide is absorbed normally through the mucosa. The reduction in systemic exposure comes from hepatic first-pass metabolism of the absorbed drug, not from a failure to cross the epithelium.
Option C: Option C is incorrect — budesonide does not bind glucocorticoid receptors irreversibly. All approved corticosteroids, including budesonide, bind GR through reversible non-covalent interactions. Irreversible binding at the site of action that prevents portal absorption is not a pharmacological mechanism of any approved corticosteroid. If budesonide bound irreversibly in ileal cells, it would be unable to recycle through the enterohepatic system and its duration of action would be prolonged beyond what is observed clinically.
Option E: Option E is incorrect — oral budesonide 9 mg/day is a pharmacologically active dose that achieves meaningful GR occupancy in intestinal mucosal cells and has been validated in multiple randomized controlled trials for induction and maintenance of remission in active ileocolonic Crohn's disease. Attributing the clinical benefit to placebo response is inconsistent with the established evidence base and misrepresents the pharmacological activity of this formulation at the approved dose.
6. A 58-year-old woman with SLE (systemic lupus erythematosus) has been taking prednisone 10 mg/day for 2 years, also on hydroxychloroquine. She undergoes an uncomplicated single-tooth extraction under local anesthesia at her dentist's office; her usual prednisone dose was taken that morning as normal. Approximately 90 minutes after the procedure, she develops nausea, dizziness, and progressive hypotension (BP 82/54 mmHg) in the waiting room. She is transported to the emergency department. There is no evidence of hemorrhage, anaphylaxis, or vasovagal syncope. A serum cortisol drawn immediately is 1.6 μg/dL. Which of the following best identifies the cause of this presentation and the error in perioperative management?
A) This patient experienced a vasovagal syncopal episode triggered by procedural anxiety; her cortisol of 1.6 μg/dL is within normal range for the perioperative stress response in a patient receiving exogenous corticosteroids, and no modification to her corticosteroid regimen was required for this minor procedure.
B) This patient developed an acute adrenal crisis precipitated by the physiological stress of the dental procedure; the perioperative management error was failure to increase her corticosteroid dose before the minor surgical stress — patients on chronic corticosteroids above the HPA suppression threshold (prednisone ≥20 mg/day for >3 weeks) undergoing minor surgery should double or triple their usual oral corticosteroid dose on the day of the procedure to cover the modest increase in cortisol demand; while prednisone 10 mg/day is below the 20 mg/day threshold for certain suppression, 2 years of therapy at any dose warrants stress dose consideration, and her cortisol of 1.6 μg/dL confirms inadequate adrenal reserve.
C) This patient had an anaphylactic reaction to the local anesthetic (lidocaine); local anesthetic anaphylaxis frequently presents as delayed hypotension 60 to 90 minutes after administration rather than immediately, and her chronic prednisone use partially suppressed the acute phase response, blunting the initial reaction while the delayed type IV hypersensitivity component progressed; treatment requires epinephrine and antihistamines, not additional corticosteroids.
D) This patient's hypotension resulted from hydroxychloroquine-induced QT prolongation causing a brief ventricular arrhythmia that spontaneously resolved; the serum cortisol of 1.6 μg/dL reflects normal post-stress cortisol suppression from the arrhythmia-associated sympathetic discharge, and the appropriate workup is an ECG and Holter monitoring rather than cortisol supplementation.
E) The presentation resulted from prednisone-induced mineralocorticoid receptor activation causing perioperative sodium retention and intravascular volume overload; the subsequent pressure natriuresis produced the acute hypotension; management requires salt restriction and furosemide, and future dental procedures should use a formulation with lower mineralocorticoid activity such as methylprednisolone.
ANSWER: B
Rationale:
This patient's presentation — progressive hypotension, nausea, dizziness, and a serum cortisol of 1.6 μg/dL in the context of a physiological stress (dental surgery) — is consistent with acute adrenal insufficiency (adrenal crisis) precipitated by an inability to mount an adequate endogenous cortisol response. She has been on prednisone 10 mg/day for 2 years. While 10 mg/day is below the commonly cited 20 mg/day threshold for certain HPA suppression, chronic corticosteroid use at any dose for an extended period (particularly beyond 3 to 6 months) can cause variable degrees of HPA axis suppression and adrenal cortical atrophy. A serum cortisol of 1.6 μg/dL during a physiological stress confirms that her adrenal cortex cannot mount the modest cortisol increase (approximately 25 to 50 mg/day equivalents) expected during minor surgical stress. The perioperative error was failing to apply stress dosing: for minor procedures (dental extraction under local anesthesia), the established approach for patients on chronic corticosteroids is to double or triple the usual oral corticosteroid dose on the day of the procedure and ensure the patient can take oral medications. She had taken her usual 10 mg that morning; taking 20 to 30 mg that morning would have been the appropriate adjustment. Emergency management now requires parenteral hydrocortisone 100 mg IV immediately, followed by IV fluid resuscitation and monitoring; the cortisol response to hydrocortisone administration and clinical stabilization will confirm the diagnosis.
Option A: Option A is incorrect — a serum cortisol of 1.6 μg/dL during hypotension following a surgical stress is not within normal range for the perioperative stress response; it is critically low and confirms adrenal insufficiency. A normal cortisol response to physiological stress should be above 18 to 20 μg/dL. Vasovagal syncope produces bradycardia and brief loss of consciousness followed by rapid recovery; it does not cause progressive hypotension persisting 90 minutes after the procedure. The cortisol result excludes a vasovagal mechanism.
Option C: Option C is incorrect — local anesthetic anaphylaxis to lidocaine is rare (true IgE-mediated allergy to amide local anesthetics is very uncommon) and does not typically present as isolated delayed hypotension 90 minutes later without urticaria, bronchospasm, or angioedema. The near-undetectable cortisol level is pathognomonic for adrenal insufficiency and is not consistent with an anaphylactic presentation. Epinephrine would be appropriate for anaphylaxis but does not address the cortisol deficiency underlying this presentation.
Option D: Option D is incorrect — hydroxychloroquine can prolong the QT interval, but QT prolongation causing ventricular arrhythmia as the mechanism for 90-minute post-procedure progressive hypotension with a cortisol of 1.6 μg/dL is not supported by the clinical picture. The cortisol result directly confirms adrenal insufficiency as the mechanism; a cardiac arrhythmia would not produce this cortisol level. An ECG is appropriate as part of the workup but does not explain the primary finding.
Option E: Option E is incorrect — prednisone 10 mg/day has modest mineralocorticoid activity, but mineralocorticoid receptor-mediated sodium retention causing pressure natriuresis and acute hypotension is not a recognized mechanism of perioperative instability in patients on this dose of prednisone. The low cortisol of 1.6 μg/dL is the central finding that establishes adrenal insufficiency as the mechanism. Furosemide would worsen the hypotension and is contraindicated in this context.
7. A 35-year-old woman at 28 weeks gestation presents in preterm labor. Ultrasound confirms a singleton pregnancy and the neonatology team recommends a course of antenatal corticosteroids to accelerate fetal lung maturity and reduce the risk of respiratory distress syndrome. The obstetric team discusses which corticosteroid to administer. The patient is currently taking low-dose prednisone 7.5 mg/day for rheumatoid arthritis that predates the pregnancy. Which of the following best identifies the correct antenatal corticosteroid choice and explains why the prednisone she is already taking is not sufficient for fetal lung maturation?
A) Prednisone is the correct choice for antenatal fetal lung maturation and the patient's existing dose of 7.5 mg/day should be increased to 40 mg/day for two doses 24 hours apart; the higher prednisone dose achieves adequate fetal lung surfactant induction by crossing the placenta directly, and no alternative corticosteroid is needed.
B) Methylprednisolone 125 mg IV is the preferred antenatal agent because its high water solubility ensures rapid placental transfer to the fetal circulation without requiring conversion; prednisone is avoided because its mineralocorticoid activity at higher doses promotes fetal sodium retention that interferes with alveolar fluid clearance at birth.
C) Dexamethasone 6 mg IM every 12 hours for four doses is an acceptable alternative to betamethasone and is used in some institutions; however, some observational data suggest it may be associated with a slightly higher risk of periventricular leukomalacia compared to betamethasone, and it is less preferred in most guidelines despite equivalent glucocorticoid potency per dose.
D) No corticosteroid is effective for fetal lung maturation when the mother is already taking systemic prednisone because the fetal HPA axis is already suppressed by transplacental prednisone exposure, and adding antenatal betamethasone or dexamethasone to a fetus with a suppressed HPA axis causes paradoxical fetal cortisol deficiency at delivery by downregulating fetal adrenal ACTH receptors.
E) Betamethasone 12 mg IM every 24 hours for two doses is the standard antenatal corticosteroid; the patient's oral prednisone at 7.5 mg/day does not provide adequate fetal lung maturation because the placenta expresses high levels of 11β-HSD2 (11-beta-hydroxysteroid dehydrogenase type 2), an enzyme that oxidizes prednisolone (the active form of prednisone) and cortisol to their inactive 11-keto metabolites — protecting the fetus from maternal glucocorticoid excess — and thereby prevents maternal prednisone from reaching the fetal circulation at pharmacologically meaningful concentrations; betamethasone and dexamethasone are poor substrates for 11β-HSD2 and cross the placenta largely intact, reaching the fetal lung at concentrations sufficient to induce surfactant synthesis.
ANSWER: E
Rationale:
This question integrates two pharmacological principles: placental glucocorticoid metabolism and antenatal corticosteroid pharmacology. The human placenta expresses high levels of 11β-HSD2 (11-beta-hydroxysteroid dehydrogenase type 2), an oxidative enzyme that converts active glucocorticoids — specifically cortisol (hydrocortisone) and prednisolone — to their inactive 11-keto forms (cortisone and prednisone respectively). This enzymatic barrier serves a critical physiological function: it protects the fetus from the maternal glucocorticoid concentrations that would otherwise suppress the developing fetal HPA axis and restrict fetal growth. The consequence for pharmacology is that when a pregnant woman takes prednisone or prednisolone, the active metabolite prednisolone is substantially inactivated by placental 11β-HSD2 before it can reach the fetal circulation in meaningful concentrations. This is precisely why prednisone and prednisolone are considered relatively safe for treatment of maternal inflammatory conditions during pregnancy — the placenta is an effective metabolic barrier against fetal exposure. However, this same barrier makes prednisone useless for inducing fetal lung surfactant synthesis, which requires the corticosteroid to reach the fetal lung. Betamethasone and dexamethasone, by contrast, are fluorinated synthetic corticosteroids that are poor substrates for 11β-HSD2 — the placenta cannot efficiently inactivate them, and they cross the placenta largely intact, reaching fetal tissues at pharmacologically active concentrations. Betamethasone 12 mg IM every 24 hours for two doses (or dexamethasone 6 mg IM every 12 hours for four doses) is the standard regimen for antenatal corticosteroid therapy because of this placental passage advantage. The patient's prednisone 7.5 mg/day provides anti-inflammatory benefit to the mother but does not and cannot substitute for antenatal betamethasone for fetal lung maturation.
Option A: Option A is incorrect — prednisone at any dose is an inappropriate choice for antenatal fetal lung maturation because it is efficiently inactivated by placental 11β-HSD2 before reaching the fetal circulation. Increasing maternal prednisone to 40 mg/day would expose the mother to high-dose corticosteroid toxicity without achieving meaningful fetal lung surfactant induction. Betamethasone or dexamethasone must be used for this indication.
Option B: Option B is incorrect — methylprednisolone is not the preferred antenatal agent for fetal lung maturation. Like prednisolone, methylprednisolone is metabolized by placental 11β-HSD2, reducing fetal exposure. Additionally, the claim that methylprednisolone's "high water solubility ensures rapid placental transfer without requiring conversion" confuses solubility with placental permeability; lipophilicity, not water solubility, facilitates passive diffusion across lipid bilayer membranes. Betamethasone and dexamethasone are the established agents for this indication.
Option C: Option C is incorrect in its framing — while the information about dexamethasone is partially accurate (it is used in some institutions and some data suggest potential differences in outcomes compared to betamethasone), this option does not explain why the patient's existing prednisone is insufficient for fetal lung maturation, which is the key pharmacological question. This option describes an alternative acceptable agent without addressing the core mechanism.
Option D: Option D is incorrect — the premise that adding antenatal betamethasone to a fetus already exposed to transplacental prednisone would cause paradoxical fetal cortisol deficiency is pharmacologically incorrect. Maternal prednisone at 7.5 mg/day does not produce meaningful fetal HPA axis suppression precisely because of placental 11β-HSD2 inactivation. The fetus is not HPA-suppressed by maternal prednisone at this dose, and antenatal betamethasone administration is both appropriate and necessary for fetal lung maturation.
8. A 72-year-old man with GOLD Group E COPD (chronic obstructive pulmonary disease) has been on triple inhaled therapy — fluticasone/vilanterol/umeclidinium — for 2 years. His blood eosinophil count is consistently 45 cells/μL across three measurements. He has experienced two community-acquired pneumonias requiring hospitalization in the past 18 months and his exacerbation rate has not decreased from his pre-ICS (inhaled corticosteroid) baseline. His pulmonologist proposes withdrawing the fluticasone component while continuing the LABA (long-acting beta-2 agonist)/LAMA (long-acting muscarinic antagonist) combination. The patient asks whether removing the ICS will cause his COPD to worsen. Which of the following best justifies the ICS withdrawal decision and addresses the patient's concern?
A) ICS withdrawal is justified in this patient because his blood eosinophil count of 45 cells/μL is below the 100 cells/μL threshold below which ICS benefit in COPD is unlikely — the eosinophil count predicts responsiveness because eosinophilic airway inflammation is corticosteroid-sensitive (driven by IL-5 and GM-CSF, suppressible by GR-mediated transrepression) while neutrophil-dominant COPD at low eosinophil counts is relatively resistant (partly due to HDAC2 impairment by oxidative stress reducing GR efficacy in the neutrophilic airway); his confirmed lack of exacerbation reduction despite 2 years of ICS and his two pneumonias — a recognized ICS class effect in COPD that is not offset by exacerbation reduction in low-eosinophil patients — together establish a negative benefit-risk balance; the WISDOM trial confirmed ICS can be withdrawn from stable COPD patients without increasing exacerbations when eosinophil counts are low and dual bronchodilator therapy is continued.
B) ICS withdrawal is not justified because the patient is on triple therapy per GOLD Group E guidelines, and triple therapy is defined as ICS + LABA + LAMA by definition; removing the ICS component converts triple therapy to dual bronchodilator therapy, which is a step-down that requires a 6-month bronchodilator optimization period and formal spirometry reassessment before it can be considered; the pneumonias are a recognized adverse effect but must be weighed against the Group E classification, which mandates triple therapy indefinitely.
C) ICS withdrawal is justified only if the patient agrees to substitute an oral corticosteroid (prednisone 5 mg/day) to maintain systemic anti-inflammatory coverage during the transition; removing ICS without systemic corticosteroid replacement risks an acute COPD exacerbation during the ICS washout period of approximately 3 to 4 weeks, after which the patient can be reassessed to determine whether the oral corticosteroid can also be tapered.
D) ICS withdrawal is not justified because the two pneumonias were infectious exacerbations of COPD rather than ICS-related adverse effects; pneumonia risk from ICS is only attributable to the drug when the causative organism is Pneumocystis jirovecii (PCP), which requires CD4 T cell suppression; community-acquired pneumonia with typical organisms reflects the patient's underlying COPD-related immune dysfunction, not ICS immunosuppression.
E) ICS withdrawal is justified because fluticasone-containing combinations have been withdrawn from the European market due to pneumonia risk in COPD; the patient should be switched to a budesonide/formoterol combination instead of full ICS withdrawal, since budesonide-containing combinations carry a lower pneumonia risk and may still provide exacerbation reduction at the patient's eosinophil count of 45 cells/μL.
ANSWER: A
Rationale:
This clinical decision integrates three lines of evidence that converge on ICS withdrawal as the appropriate action. First, the eosinophil biomarker: blood eosinophil counts consistently at 45 cells/μL — substantially below the 100 cells/μL threshold associated with ICS benefit and far below the 300 cells/μL level associated with maximum benefit — identifies this patient as having predominantly neutrophilic COPD airway inflammation. Neutrophilic COPD is relatively corticosteroid-resistant for reasons that include HDAC2 impairment by the oxidative stress of cigarette smoke and activated neutrophils; damaged HDAC2 cannot effectively deacetylate histones at NF-κB-driven pro-inflammatory promoters even when GR is fully activated by the ICS, blunting the transrepression effect. Second, the clinical outcome confirms the biomarker prediction: two years of ICS have not reduced the exacerbation rate. The pharmacological prediction (low eosinophils → minimal ICS benefit) is confirmed by the clinical observation (no exacerbation reduction). Third, the harm profile: ICS use in COPD specifically and dose-dependently increases pneumonia risk — a risk that is not associated with equivalent ICS use in asthma — and two hospitalizations for pneumonia in 18 months represent significant ICS-attributable harm in a patient with no demonstrable benefit. The WISDOM trial demonstrated that ICS can be withdrawn from stable COPD patients on dual bronchodilator therapy without increasing exacerbation rates when blood eosinophil counts are low, directly validating this clinical decision.
Option B: Option B is incorrect — GOLD Group E classification does not mandate indefinite triple therapy in the face of confirmed non-response and significant drug-attributable harm. GOLD guidelines are explicitly designed to allow individualized benefit-risk assessment including ICS withdrawal in patients with low eosinophil counts and ICS-related adverse effects. The guideline supports step-down de-escalation of ICS in exactly this clinical profile, and the WISDOM trial data are specifically incorporated into this recommendation.
Option C: Option C is incorrect — substituting oral prednisone 5 mg/day during ICS withdrawal is not clinically indicated and would expose the patient to the systemic side effects of oral corticosteroids without evidence of benefit in low-eosinophil COPD. ICS withdrawal does not require systemic corticosteroid bridging; the risk of acute exacerbation during ICS washout in low-eosinophil patients is not established, and the WISDOM trial demonstrated safe ICS withdrawal without this intervention.
Option D: Option D is incorrect — ICS-related pneumonia in COPD is not restricted to Pneumocystis jirovecii pneumonia (PCP) requiring CD4 T cell suppression. ICS at the doses used in COPD management suppress local airway innate immune defenses against typical bacterial pathogens including Streptococcus pneumoniae and Haemophilus influenzae through GR-mediated transrepression of pro-inflammatory cytokines and reduced mucosal immune cell function. Community-acquired bacterial pneumonia is the most common ICS-attributable pneumonia type in COPD clinical trials.
Option E: Option E is incorrect — fluticasone-containing ICS combinations have not been withdrawn from the European market due to pneumonia risk in COPD; they remain available and guideline-recommended for appropriate patients. While some comparative analyses do suggest lower absolute pneumonia rates with budesonide-containing versus fluticasone-containing combinations, switching from ICS withdrawal to an alternative ICS formulation is not appropriate in a patient with consistently low eosinophils and confirmed ICS non-response. The correct action is ICS withdrawal, not ICS substitution.
9. A 47-year-old woman with inflammatory polymyositis had been taking prednisone 30 mg/day for 6 weeks prescribed by her rheumatologist. During a hospital admission for an unrelated procedure, a covering internal medicine physician — unaware of her corticosteroid history — discontinued the prednisone abruptly on discharge without tapering instructions. Five days later she presents to the emergency department with severe fatigue, anorexia, nausea, diffuse myalgias, and orthostatic hypotension (BP 88/60 mmHg supine, dropping to 72/48 mmHg standing). Laboratory results show sodium 131 mEq/L, potassium 4.2 mEq/L, blood glucose 58 mg/dL, and a serum cortisol of 1.8 μg/dL. Which of the following best identifies the diagnosis and the appropriate immediate management?
A) This patient has a polymyositis flare triggered by abrupt corticosteroid withdrawal; the hyponatremia and hypoglycemia reflect nutritional deficiency from disease-related myophagia, and the cortisol of 1.8 μg/dL represents appropriate hypothalamic-pituitary suppression from the recent prednisone course; treatment requires resumption of prednisone at the prior dose and nutritional supplementation.
B) This patient has primary adrenal insufficiency (Addison disease) that was unmasked by corticosteroid withdrawal; the hyponatremia and hyperkalemia confirm aldosterone deficiency with sodium wasting and potassium retention, and she requires lifelong glucocorticoid and mineralocorticoid replacement; the prednisone course was masking her primary adrenal insufficiency.
C) This patient has secondary adrenal insufficiency from abrupt withdrawal of exogenous corticosteroid; after 6 weeks of prednisone 30 mg/day, the HPA axis is suppressed and the adrenal cortex has atrophied — abrupt discontinuation leaves the patient unable to generate endogenous cortisol; the presentation is distinguished from primary adrenal insufficiency by the normal potassium (4.2 mEq/L), confirming preserved aldosterone secretion through the intact RAAS (renin-angiotensin-aldosterone system); immediate treatment requires IV hydrocortisone 100 mg bolus followed by continuous infusion or repeat dosing, IV fluids for hemodynamic stabilization, dextrose for hypoglycemia, and subsequent gradual taper of corticosteroids after clinical stabilization.
D) This patient has a hyponatremia of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) caused by prednisone withdrawal triggering a pain-mediated ADH (antidiuretic hormone) surge; the hypotension and hypoglycemia are secondary to the hyponatremia-driven cerebral edema causing autonomic dysregulation; treatment requires fluid restriction and hypertonic saline, not corticosteroids.
E) This patient has acute polymyositis-associated cardiomyopathy causing cardiogenic shock; polymyositis frequently involves cardiac muscle, and abrupt corticosteroid discontinuation allows myocardial inflammation to progress rapidly; the low cortisol reflects a stress response failure secondary to cardiogenic shock rather than primary HPA axis suppression; treatment requires urgent echocardiography and cardiac support, not empirical corticosteroid supplementation.
ANSWER: C
Rationale:
This presentation is a textbook case of secondary adrenal insufficiency (SAI) from abrupt exogenous corticosteroid withdrawal. After 6 weeks of prednisone 30 mg/day — well above the 20 mg/day threshold for HPA axis suppression and well beyond the 3-week duration threshold — the patient's hypothalamus and pituitary have been under sustained negative feedback from exogenous corticosteroid, suppressing CRH and ACTH secretion. The adrenal cortex, deprived of ACTH stimulation, has undergone cortical atrophy and lost its steroidogenic capacity. When prednisone is abruptly discontinued, the HPA axis cannot recover rapidly enough to generate cortisol to meet basal and stress requirements; endogenous cortisol production remains critically impaired, as confirmed by the cortisol of 1.8 μg/dL. The clinical presentation — fatigue, anorexia, nausea, myalgias, hypotension — is the classic glucocorticoid deficiency syndrome. Crucially, the laboratory findings distinguish SAI from primary adrenal insufficiency (Addison disease): potassium is 4.2 mEq/L (normal), confirming that aldosterone production is preserved. In SAI, the adrenal medulla and zona glomerulosa are structurally intact; aldosterone secretion continues because it is regulated by the renin-angiotensin system rather than ACTH. The hyponatremia (131 mEq/L) reflects water retention from cortisol deficiency (cortisol normally suppresses ADH secretion), not salt wasting from mineralocorticoid deficiency. Immediate management: IV hydrocortisone 100 mg bolus (providing both glucocorticoid replacement and the mineralocorticoid cover needed for hemodynamic stabilization at this dose), IV 0.9% saline for volume replacement, and IV or oral glucose for hypoglycemia. After stabilization, hydrocortisone is continued at 50 mg IV every 6 to 8 hours, then transitioned to oral prednisone and tapered gradually.
Option A: Option A is incorrect — while a polymyositis flare is possible after corticosteroid discontinuation, the laboratory findings — cortisol 1.8 μg/dL, hypoglycemia, and hyponatremia — are not features of a disease flare; they are features of cortisol deficiency. A myositis flare would present with worsening proximal weakness and elevated CK, not hypotension, hypoglycemia, and near-undetectable cortisol. The characterization of cortisol 1.8 μg/dL as "appropriate hypothalamic-pituitary suppression" misrepresents this critically low value during a physiological stress.
Option B: Option B is incorrect — the normal potassium (4.2 mEq/L) effectively excludes primary adrenal insufficiency as the primary diagnosis. Primary adrenal insufficiency destroys both the cortisol-producing zona fasciculata and the aldosterone-producing zona glomerulosa, producing hyperkalemia from aldosterone deficiency. The preserved potassium in this patient confirms intact aldosterone secretion and therefore intact zona glomerulosa function, pointing to secondary (not primary) adrenal insufficiency. Additionally, a 6-week prednisone course does not "unmask" pre-existing Addison disease — it suppresses the HPA axis and causes SAI.
Option D: Option D is incorrect — SIADH causing the hyponatremia is not the primary diagnosis here. While cortisol deficiency can contribute to hyponatremia through excess ADH secretion, the central finding of serum cortisol 1.8 μg/dL during hemodynamic compromise establishes adrenal insufficiency as the primary mechanism. SIADH does not cause hypotension, hypoglycemia, or a serum cortisol of 1.8 μg/dL. Fluid restriction in this hemodynamically unstable patient would worsen hypotension.
Option E: Option E is incorrect — while polymyositis can involve cardiac muscle, the clinical presentation here — with cortisol 1.8 μg/dL, hypoglycemia, and hyponatremia within 5 days of abrupt corticosteroid withdrawal — is pharmacologically explained by secondary adrenal insufficiency. Cardiogenic shock would not produce this cortisol level or the hyponatremia/hypoglycemia pattern, and empirical corticosteroid supplementation must not be withheld pending echocardiography when adrenal crisis is the most likely diagnosis with a cortisol of 1.8 μg/dL in this clinical context.
10. A 62-year-old man with asthma-COPD overlap syndrome (ACO) has a blood eosinophil count of 450 cells/μL and an FEV1 (forced expiratory volume in 1 second) of 58% predicted. He has been on medium-dose budesonide 400 μg/day as monotherapy but continues to have exacerbations. His pulmonologist plans to add formoterol (a LABA) rather than double the budesonide dose to 800 μg/day. The patient asks why adding a second drug class is more effective than simply taking more of his current inhaler. Which of the following best explains the pharmacological rationale for the ICS-LABA combination over ICS dose escalation in this patient?
A) Doubling the budesonide dose to 800 μg/day would exceed the maximum safe cumulative ICS dose for his age and sex, triggering mandatory FDA (Food and Drug Administration) monitoring requirements for HPA axis function; adding formoterol avoids this regulatory threshold while achieving superior bronchodilation through a complementary mechanism that does not involve the glucocorticoid receptor.
B) LABAs (long-acting beta-2 agonists) such as formoterol are anti-inflammatory agents that independently suppress NF-κB (nuclear factor kappa B) transcription in airway eosinophils through a beta-2 receptor-mediated pathway that is distinct from and non-overlapping with GR-mediated transrepression; their anti-inflammatory effects are therefore purely additive to ICS, producing twice the cytokine suppression at the same ICS dose.
C) Adding formoterol achieves superior smooth muscle relaxation through beta-2 adrenoceptor-mediated cAMP elevation — a mechanism entirely distinct from budesonide's anti-inflammatory effects — and the two drugs together address both components of airflow obstruction (inflammation and bronchoconstriction) simultaneously, while doubling the budesonide dose would only address the inflammatory component without improving smooth muscle tone.
D) The ICS-LABA combination achieves pharmacodynamic synergy through two complementary mechanisms: formoterol activates beta-2 adrenoceptors, raising intracellular cAMP and activating PKA (protein kinase A), which phosphorylates GR at serine residues that enhance GR nuclear translocation and transcriptional activity — meaning formoterol sensitizes airway cells to budesonide at the current dose; simultaneously, budesonide suppresses the inflammatory cytokine milieu (particularly IL-4, IL-13, and TNF-α) that accelerates beta-2 adrenoceptor internalization and downregulation, preserving long-term formoterol responsiveness; together these bidirectional interactions produce greater anti-inflammatory and bronchodilator efficacy than either agent alone at the same total dose, and clinical trial evidence (including the SMART trial logic) establishes that doubling ICS dose alone is inferior to adding LABA at the same ICS dose at GINA Step 3.
E) Doubling budesonide from 400 to 800 μg/day produces a flat dose-response relationship because the glucocorticoid receptor in airway cells is already fully saturated at 400 μg/day; no additional GR occupancy or anti-inflammatory gene modulation is possible above this dose, making any further ICS dose increase pharmacologically futile regardless of disease severity or eosinophil count.
ANSWER: D
Rationale:
The pharmacodynamic rationale for ICS-LABA combination over ICS dose escalation rests on genuine bidirectional molecular synergy between the two drug classes, as established in the GINA Step 3 recommendation. In the first direction, LABA-to-ICS potentiation: formoterol activates beta-2 adrenoceptors on airway epithelial cells, smooth muscle cells, and inflammatory cells, elevating intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates GR at Ser211 (a known activating phosphorylation site), promoting GR nuclear translocation and enhancing the transcriptional activity of the GR already present and activated by budesonide. The net effect is that the existing dose of budesonide achieves greater anti-inflammatory gene regulation — NF-κB transrepression of IL-5, IL-8, and GM-CSF is enhanced without increasing the budesonide dose. In the second direction, ICS-to-LABA potentiation: budesonide suppresses the Th2 inflammatory cytokine milieu in asthmatic airways, particularly IL-4 and IL-13, which normally accelerate beta-2 adrenoceptor internalization and downregulation through G protein-coupled receptor kinase (GRK)-mediated mechanisms. By reducing this cytokine-driven receptor downregulation, budesonide preserves beta-2 receptor surface density and maintains formoterol efficacy over time. Clinical trial evidence establishes that this bidirectional synergy produces superior outcomes (exacerbation reduction, FEV1 improvement) compared to doubling the ICS dose at Step 3. Doubling from 400 to 800 μg/day does provide incremental benefit but is consistently shown to be inferior to adding LABA — supporting the clinical decision to add formoterol.
Option A: Option A is incorrect — there is no FDA regulatory threshold or mandatory monitoring requirement triggered by doubling inhaled budesonide from 400 to 800 μg/day. Standard ICS dosing ranges include medium (400 μg/day) and high (800 μg/day or above) doses, and transitions between these ranges are clinical decisions without mandatory regulatory monitoring obligations. The rationale for adding formoterol is pharmacodynamic synergy, not regulatory avoidance.
Option B: Option B is incorrect — while LABAs do have some immunomodulatory effects in airway cells, characterizing LABAs as independently suppressing NF-κB transcription in eosinophils through a beta-2 receptor pathway that is non-overlapping with GR-mediated transrepression and producing "twice the cytokine suppression" is an overstatement. The primary rationale for ICS-LABA combination is the bidirectional pharmacodynamic synergy described above, not independent LABA anti-inflammatory activity equivalent to adding a second ICS mechanism.
Option C: Option C is incorrect — while it is true that formoterol provides bronchodilation through a mechanism distinct from budesonide's anti-inflammatory effects, this option presents an incomplete explanation that omits the bidirectional molecular synergy between the two drug classes. The full rationale for preferring ICS-LABA over ICS dose doubling includes both the pharmacodynamic synergy (GR sensitization and beta-2 receptor preservation) and the bronchodilator contribution, not just the latter.
Option E: Option E is incorrect — the glucocorticoid receptor in airway cells is not fully saturated at an inhaled budesonide dose of 400 μg/day for all patients in all clinical contexts. While receptor occupancy does increase with dose in a non-linear fashion and there is diminishing return with dose escalation, the claim of complete receptor saturation at 400 μg/day is an oversimplification. The preferred clinical rationale for adding LABA rather than doubling ICS is the bidirectional synergy — not that higher ICS doses are completely futile.
11. A 55-year-old woman with SLE (systemic lupus erythematosus) has been on methylprednisolone 32 mg/day for 10 weeks for a severe nephritis flare, now being tapered. She reports progressive bilateral hip and thigh discomfort over the past 3 weeks, worse with weight-bearing on the right side. On examination, she has mild bilateral proximal lower extremity weakness on manual muscle testing, and hip range of motion is mildly limited and painful on the right. Creatine kinase (CK) is 54 U/L (normal). MRI of both hips shows bilateral subchondral low-signal intensity in the femoral heads with a right-sided crescent sign. Which of the following best identifies the primary complication responsible for this presentation and distinguishes it from the other corticosteroid-related musculoskeletal complication in this differential?
A) The presentation represents corticosteroid-induced myopathy; the proximal lower extremity weakness is classic for the type IIb skeletal muscle fiber atrophy caused by GRE-driven transcription of muscle-specific ubiquitin ligases (MuRF1 and Atrogin-1) that promote myofibrillar protein degradation; the normal CK confirms that myopathy rather than inflammatory myositis is present; the hip pain and limited range of motion are secondary to muscle weakness causing altered joint mechanics; MRI changes in the femoral head in corticosteroid myopathy reflect bone marrow edema from disuse osteoporosis, not avascular necrosis.
B) The primary complication is corticosteroid-induced avascular necrosis (osteonecrosis) of the femoral heads; the MRI findings — bilateral subchondral low signal in the femoral heads with a crescent sign on the right — are pathognomonic for osteonecrosis, not myopathy; corticosteroid-induced myopathy produces painless proximal weakness with a normal CK and no MRI abnormality in bone, while osteonecrosis produces bone pain exacerbated by weight-bearing, limited range of motion, and characteristic MRI signal change; both complications can coexist at high doses, but the MRI finding definitively identifies osteonecrosis as the dominant process driving hip pain and limited motion in this patient.
C) The presentation represents a severe lupus myositis flare — not a corticosteroid complication — triggered by the methylprednisolone taper; reduced corticosteroid exposure during tapering has allowed SLE-related muscle inflammation to re-emerge, and the normal CK reflects early myositis before enzyme leakage begins; the MRI femoral head changes represent stress fractures from lupus-associated antiphospholipid syndrome causing bone marrow infarction, not corticosteroid osteonecrosis.
D) The presentation represents corticosteroid-induced osteoporosis with bilateral femoral neck stress fractures; the RANKL/OPG imbalance after 10 weeks of high-dose methylprednisolone has produced rapid subchondral trabecular collapse in both femoral necks, and the proximal weakness reflects referred pain from the fracture sites causing voluntary movement limitation; the MRI findings are consistent with acute insufficiency fractures, and urgent orthopedic consultation for prophylactic femoral nailing is required.
E) The presentation is a corticosteroid withdrawal syndrome; the reduction in methylprednisolone dose has produced a systemic inflammatory rebound driven by upregulation of pro-inflammatory cytokines that were previously suppressed, causing diffuse myalgia and arthralgia that mimic myopathy and arthritis; the MRI changes reflect reactive synovitis in the hip joints rather than osteonecrosis, and the correct management is to increase methylprednisolone back to the pre-taper dose until the withdrawal syndrome resolves.
ANSWER: B
Rationale:
The MRI findings are the diagnostic key in this case. The combination of bilateral subchondral low-signal intensity in the femoral heads with a right-sided crescent sign is pathognomonic for avascular necrosis (osteonecrosis), not for any other corticosteroid complication. The crescent sign specifically represents subchondral fracture at the necrotic bone-viable bone interface — a late but specific MRI finding of osteonecrosis. This case requires distinguishing osteonecrosis from corticosteroid-induced myopathy, which can coexist and both involve proximal lower extremity symptoms at high corticosteroid doses. Corticosteroid myopathy is caused by GRE-driven transactivation of muscle-specific E3 ubiquitin ligases (MuRF1 and Atrogin-1) in skeletal muscle, promoting myofibrillar protein catabolism and type IIb fast-twitch fiber atrophy. Its clinical signature is painless proximal muscle weakness (characteristically symmetric, affecting hip flexors and shoulder abductors first), a normal or minimally elevated CK (muscle fiber atrophy does not cause membrane disruption and enzyme leak), no joint pain, preserved range of motion, and no MRI bone abnormality. Osteonecrosis, by contrast, produces bone pain that is characteristically exacerbated by weight-bearing, limited and painful range of motion of the affected joint, and the characteristic MRI subchondral signal changes and crescent sign. The normal CK in this patient is consistent with myopathy (and argues against inflammatory myositis), but the MRI findings establish osteonecrosis as the primary process responsible for the hip pain, limited range of motion, and weight-bearing discomfort. Both complications may be present simultaneously, but the MRI provides the definitive anatomical diagnosis for the joint symptoms.
Option A: Option A is incorrect — this option misidentifies the MRI findings as representing bone marrow edema from disuse osteoporosis rather than osteonecrosis. The subchondral low signal pattern combined with a crescent sign is not the MRI appearance of disuse osteoporosis or bone marrow edema; it is the pathognomonic appearance of osteonecrosis. Additionally, corticosteroid myopathy does not cause hip pain or limited range of motion — these symptoms point to a joint or bone pathology, not to myopathy.
Option C: Option C is incorrect — the normal CK argues against active inflammatory myositis (in which CK is typically markedly elevated, often 10 to 50 times normal). Additionally, antiphospholipid syndrome causing bone marrow infarction can produce osteonecrosis, but the clinical context — 10 weeks of high-dose methylprednisolone followed by this presentation — makes corticosteroid-induced osteonecrosis far more likely than antiphospholipid syndrome-related infarction as the primary diagnosis, and the MRI appearance is consistent with the former.
Option D: Option D is incorrect — the MRI appearance described (bilateral subchondral femoral head signal change with crescent sign) is not the MRI appearance of femoral neck stress fractures or insufficiency fractures from osteoporosis, which would show a linear low-signal band perpendicular to the femoral neck cortex, not subchondral signal change in the femoral head. The crescent sign is specific to osteonecrosis and should not be described as an insufficiency fracture pattern.
Option E: Option E is incorrect — corticosteroid withdrawal syndrome can cause myalgias and arthralgias during tapering, but it does not produce the MRI findings of subchondral femoral head signal abnormality with crescent sign. Reactive synovitis causes joint effusion and synovial enhancement on MRI, not subchondral bone signal change. The MRI findings in this patient are not consistent with a withdrawal syndrome and require orthopedic evaluation for osteonecrosis management.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.